A Phase 1/2 interventional study of VRx-3996 and valganciclovir in Epstein-Barr Virus-Associated Lymphoma and Lymphoproliferative Disorders, sponsored by Viracta Therapeutics, Inc.. Completed at 28 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-20.
Sponsored by Viracta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies in Lymphoproliferative Disorders with a site in United States — 28 open to participants now, 46 under way, 2 of them phase 3. Lymphoproliferative Disorders · United States.
Among the 147 studies in Lymphoproliferative Disorders with a site in United States, this one is the 45th largest by enrollment of the 127 interventional ones that give a count, is one of 8 that started in 2018, is one of 19 in phase 1/2, and was the 106th registered.
216 studies on the registry are indexed under Lymphoproliferative Disorders; 49 are open to participants now.
Browse Lymphoproliferative Disorders studies →28 of the 147 studies in Lymphoproliferative Disorders with a site in United States are open now. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Kelonia Therapeutics, Inc. · Sites in United States, Australia
Ages 18+
Timothy Voorhees · Sites in United States
Ages 18+
Jennifer Amengual · Sites in United States
Ages 15+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 39 Lymphoproliferative Disorders studies recruiting now, 28 (72%) set no upper age limit and 6 (15%) stop at 75 or younger; 18 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 68 · Phase 3 15
First in 1995; this study’s year is marked. 8 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 64 is above the median of 41 across 173 interventional studies indexed under Lymphoproliferative Disorders.
Median enrollment 37 across the 127 interventional studies, 250 across the 17 observational. Of the 94 that completed or were terminated, 39 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 147 have an industry lead sponsor. The 10 most frequent:
Viracta Therapeutics, Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.
Viracta Therapeutics, Inc. has 1 study filed under Lymphoproliferative Disorders — fewer than ten, so there is no comparison to draw.
15 of the studies in Lymphoproliferative Disorders with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT03467867Georgetown UniversityA Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL | 2026-12 |
| NCT06271252OriCell Therapeutics Co., Ltd.A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study | 2026-12-12 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
| NCT06672705Timothy VoorheesEpcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphoproliferative Disorders | 2026-12-31 |
Add all 15 to your calendar (.ics) → With an account.
Among the 147 studies in Lymphoproliferative Disorders with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A two part, Phase 1b/2 study to define a recommended Phase 2 dose of VRx-3996 in combination with valganciclovir (Phase 1b) designed to evaluate the efficacy of this combination in relapsed/refractory Epstein-Barr Virus Associated Lymphoma (EBV+ lymphomas).
The purpose of this study is to determine whether VRx-3996 in combination with valganciclovir is safe, determine the side effect profile, and to determine whether this therapy may help patients with EBV-related lymphomas. The study has two phases. Goals of the first phase include determining a safe and tolerable dose that can be administered in phase 2. Goals of the second phase include further evaluating the safety and tolerability of VRx-3996 in combination with valganciclovir, evaluating how the drugs are metabolized in the body, evaluating response rates and other exploratory objectives that will help the researchers evaluate how these drugs work in the body. Participants will receive daily oral doses of the two study drugs and will have multiple study visits where they will have blood collected, physical examinations, and other medical monitoring. Following completion of the Ph2, the study will enroll additional patients into a Tablet Pharmacokinetic (PK) cohort to investigate the PK parameters of the tablet formulation.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
VRx-3996 (cohort 1) and valganciclovir VRx-3996 (cohort 2) and valganciclovir VRx-3996 (cohort 3) and valganciclovir VRx-3996 (cohort 4) and valganciclovir VRx-3996 (cohort 5) and valganciclovir
Combination Product: VRx-3996 and valganciclovir
VRx-3996 and valganciclovir at the recommended Phase 2 dose (RP2D)
Combination Product: VRx-3996 and valganciclovir
VRx-3996 and valganciclovir at the recommended Phase 2 dose (RP2D)
Combination Product: VRx-3996 and valganciclovir
Drug pages: NanatinostatStudies of NanatinostatNanatinostat pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ValganciclovirStudies of ValganciclovirValganciclovir pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
second-generation histone deacetylase (HDAC) inhibitor, nanatinostat (previously referred to as either VRx-3996 or CHR-3396)
Also known as: nanatinostat, ganciclovir, Chroma (CHR)-3996
Number (Proportion) of Participants With Adverse Events (AEs)
Number (percentage) of patients experiencing at least one treatment-emergent adverse event, defined as those untoward medical events with onset after the first dose of study drug or existing events that worsened after the first dose during the study
Time frame: Up to approximately 2 years
Number (Proportion) of Participants With Dose-Limiting Toxicities (DLTs) in Phase 1b
Number (percentage) of patients experiencing a DLT during the first cycle (28 days) of study treatment in Phase 1b, defined as an adverse event (AE) or clinically significant abnormal laboratory value that was at least possibly related to study drugs and was not primarily related to disease, disease progression, concomitant medication(s), or intercurrent illness. In addition, to be considered a DLT, the AE had to meet at least one of the following criteria: * Grade 4 anemia unexplained by underlying disease * Grade 4 febrile neutropenia * Grade 4 neutropenia lasting \>5 days * Any other Grade 4 hematologic toxicity (thrombocytopenia, neutropenia, febrile neutropenia, anemia) of any duration * Grade 4 or higher tumor lysis syndrome * Grade 3 or higher thrombocytopenia (with or without bleeding) * Any requirement for platelet transfusion * Grade 3 or higher non-hematologic toxicity despite adequate supportive care * Results in a dose hold of \>7 consecutive days
Time frame: Cycle 1 (28 days)
Overall Response Rate
Number (percentage) of patients with a best overall complete response (CR) or partial response (PR) according to the Lugano 2014 criteria (Cheson, Bruce D. et al. J Clin Oncology 2014;32(27):3059-68), where CR included complete metabolic response (no/minimal fluorodeoxyglucose \[FDG\] uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions, and PR included partial metabolic response (reduced FDG uptake compared with baseline) or radiologic response (target lesions ≤ 50% decrease in the sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites)
Time frame: Up to approximately 2 years
Duration of Response
Interval of time from date of first observed complete or partial response per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) to the date of documented disease progression or death due to any cause, where disease progression is defined by Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) as progressive metabolic disease (increase in fluorodeoxyglucose \[FDG\] uptake from baseline or new FDG-avid foci consistent with lymphoma) or progressive radiologic response (increase in the product of perpendicular diameters of a single node by ≥ 50% or emergence of a new lesion)
Time frame: Up to approximately 2 years
Time to Response
Interval of time from the start of study drug treatment to the first documentation of CR or PR per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68)
Time frame: Up to approximately 2 years
Progression-Free Survival
Interval of time from the date of first study drug administration to the documented date of disease progression or death, whichever occurred first, where disease progression is defined by Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) as progressive metabolic disease (increase in fluorodeoxyglucose \[FDG\] uptake from baseline or new FDG-avid foci consistent with lymphoma) or progressive radiologic response (increase in the product of perpendicular diameters of a single node by ≥ 50% or emergence of a new lesion)
Time frame: Up to approximately 2 years
Disease Control Rate
Number (percentage) of patients with CR, PR, or stable disease (SD) per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68)
Time frame: Up to approximately 2 years
Overall Survival
Interval of time from date of first study drug treatment to date of death, for any reason (patients without documentation of death at the time of analysis were censored at the date the patient was last known to be alive)
Time frame: Up to approximately 2 years
Cmax (ng/mL) of VRx-3996
Pharmacokinetic (PK) assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on cycle 1 day 1 (C1D1) and cycle 2 day 2 (C2D1)
Time frame: Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
Cmax (ng/mL) of Valganciclovir
PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1
Time frame: Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
Area Under Curve (AUC) 0-t of VRx-3996
PK assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1
Time frame: Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
AUC 0-t of of Valganciclovir
PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1
Time frame: Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
Half-life of VRx-3996
PK assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1
Time frame: Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
Half-life of Valganciclovir
PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1
Time frame: Phase 1b: Cycle 1 Day 1 and Phase 2: multiple doses through Cycle 2 Day 1
| Milestone | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Expansion - Tablet |
|---|---|---|---|---|---|---|---|
| Started | 7 | 5 | 4 | 4 | 5 | 30 | 9 |
| Completed | 7 | 5 | 4 | 4 | 5 | 30 | 9 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Number (percentage) of patients experiencing at least one treatment-emergent adverse event, defined as those untoward medical events with onset after the first dose of study drug or existing events that worsened after the first dose during the study
| Participants | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Dose Expansion - Tablet |
|---|---|---|---|---|---|---|---|
| Number (Proportion) of Participants With Adverse Events (AEs) | 7 | 5 | 4 | 4 | 5 | 30 | 9 |
Number (percentage) of patients experiencing a DLT during the first cycle (28 days) of study treatment in Phase 1b, defined as an adverse event (AE) or clinically significant abnormal laboratory value that was at least possibly related to study drugs and was not primarily related to disease, disease progression, concomitant medication(s), or intercurrent illness. In addition, to be considered a DLT, the AE had to meet at least one of the following criteria: * Grade 4 anemia unexplained by underlying disease * Grade 4 febrile neutropenia * Grade 4 neutropenia lasting \>5 days * Any other Grade 4 hematologic toxicity (thrombocytopenia, neutropenia, febrile neutropenia, anemia) of any duration * Grade 4 or higher tumor lysis syndrome * Grade 3 or higher thrombocytopenia (with or without bleeding) * Any requirement for platelet transfusion * Grade 3 or higher non-hematologic toxicity despite adequate supportive care * Results in a dose hold of \>7 consecutive days
| Participants | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 (RP2D) |
|---|---|---|---|---|---|
| Number (Proportion) of Participants With Dose-Limiting Toxicities (DLTs) in Phase 1b | 4 | 0 | 0 | 0 | 0 |
Number (percentage) of patients with a best overall complete response (CR) or partial response (PR) according to the Lugano 2014 criteria (Cheson, Bruce D. et al. J Clin Oncology 2014;32(27):3059-68), where CR included complete metabolic response (no/minimal fluorodeoxyglucose \[FDG\] uptake) and radiologic response (target lesions regress to ≤1.5 cm in longest transverse diameter of a lesion) and no new lesions, and PR included partial metabolic response (reduced FDG uptake compared with baseline) or radiologic response (target lesions ≤ 50% decrease in the sum of the product of perpendicular diameters of up to 6 target measurable nodes and extranodal sites)
| Participants | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Dose Expansion - Tablet |
|---|---|---|---|---|---|---|---|
| Complete Response | 2 | 1 | 0 | 0 | 1 | 3 | 1 |
| Partial Response | 1 | 1 | 1 | 0 | 2 | 4 | 1 |
| Stable Disease | 1 | 0 | 0 | 1 | 1 | 5 | 1 |
| Progressive Disease | 2 | 0 | 1 | 3 | 1 | 11 | 5 |
Interval of time from date of first observed complete or partial response per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) to the date of documented disease progression or death due to any cause, where disease progression is defined by Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) as progressive metabolic disease (increase in fluorodeoxyglucose \[FDG\] uptake from baseline or new FDG-avid foci consistent with lymphoma) or progressive radiologic response (increase in the product of perpendicular diameters of a single node by ≥ 50% or emergence of a new lesion)
| days | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Dose Expansion - Tablet |
|---|---|---|---|---|---|---|---|
| Duration of Response | 825.5 (160.0 to NA) | 116.5 (34.0 to NA) | 113.0 (NA to NA) | — | NA (127.0 to NA) | 634.0 (80.0 to NA) | NA (57.0 to NA) |
Interval of time from the start of study drug treatment to the first documentation of CR or PR per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68)
| days | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Expansion - Capsule | Phase 2 Expansion - Tablet |
|---|---|---|---|---|---|---|---|
| Time to Response | NA (33.0 to NA) | 52.5 (51.0 to NA) | NA (50.0 to NA) | — | NA (57.0 to NA) | 162.0 (58.0 to NA) | NA (58.0 to NA) |
Interval of time from the date of first study drug administration to the documented date of disease progression or death, whichever occurred first, where disease progression is defined by Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68) as progressive metabolic disease (increase in fluorodeoxyglucose \[FDG\] uptake from baseline or new FDG-avid foci consistent with lymphoma) or progressive radiologic response (increase in the product of perpendicular diameters of a single node by ≥ 50% or emergence of a new lesion)
| days | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Expansion - Capsule | Phase 2 Expansion - Tablet |
|---|---|---|---|---|---|---|---|
| Progression-Free Survival | 209.0 (57.0 to NA) | 168.0 (87.0 to NA) | 107.5 (53.0 to NA) | 55.5 (15.0 to NA) | 185.0 (10.0 to NA) | 66.0 (56.0 to 220.0) | 52.5 (34.0 to 114.0) |
Number (percentage) of patients with CR, PR, or stable disease (SD) per Lugano 2014 criteria (Cheson BD et al. J Clin Oncology 2014;32(27):3059-68)
| Participants | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Expansion - Capsule | Phase 2 Expansion - Tablet |
|---|---|---|---|---|---|---|---|
| Disease Control Rate | 4 | 2 | 1 | 1 | 4 | 12 | 3 |
Interval of time from date of first study drug treatment to date of death, for any reason (patients without documentation of death at the time of analysis were censored at the date the patient was last known to be alive)
| days | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Expansion - Capsule | Phase 2 Expansion - Tablet |
|---|---|---|---|---|---|---|---|
| Overall Survival | 227.0 (122.0 to NA) | 578.0 (486.0 to NA) | NA (328.0 to NA) | 168.5 (32.0 to NA) | 496.0 (49.0 to NA) | 801.0 (315.0 to NA) | NA (106.0 to NA) |
Pharmacokinetic (PK) assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on cycle 1 day 1 (C1D1) and cycle 2 day 2 (C2D1)
| ng/mL | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohorts 1, 2b and 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 RP2D - Capsule | Phase 2 RP2D - Tablet |
|---|---|---|---|---|---|
| Single-dose | 29.8 ± 26.7 | 83.3 ± 38.1 | 214 ± 140 | 196 ± 166 | 298 ± 137 |
| Multiple-dose | — | — | — | 334 ± 283 | 238 ± 208 |
PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1
| ng/mL | Phase 1b Dose Escalation - 450 mg | Phase 1b Dose Escalation - 900 mg | Phase 2 RP2D - Capsule (VRx-3996) | Phase 2 RP2D - Tablet (VRx-3996) |
|---|---|---|---|---|
| Single-Dose | 4230 ± 1348 | 6712 ± 1495 | 7300 ± 2790 | 14900 ± 8380 |
| Multiple-Dose | — | — | 8690 ± 5800 | 14200 ± 7060 |
PK assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1
| h*ng/mL | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohorts 1, 2b and 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 RP2D - Capsule | Phase 2 RP2D - Tablet |
|---|---|---|---|---|---|
| Single-dose | 128 ± 67.0 | 229 ± 76.4 | 340 ± 384 | 417 ± 299 | 587 ± 212 |
| Multiple-dose | — | — | — | 638 ± 418 | 474 ± 268 |
PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1
| h*ng/mL | Phase 1b Dose Escalation - 450 mg | Phase 1b Dose Escalation - 900 mg | Phase 2 RP2D - Capsule (VRx-3996) | Phase 2 RP2D - Tablet (VRx-3996) |
|---|---|---|---|---|
| Single-dose | 15600 ± 4160 | 24400 ± 9300 | 25200 ± 10400 | 49700 ± 29100 |
| Multiple-dose | — | — | 28300 ± 16400 | 46600 ± 18000 |
PK assessment of VRx-3996 pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1
| hours | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohorts 1, 2b and 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 RP2D - Capsule | Phase 2 RP2D - Tablet |
|---|---|---|---|---|---|
| Single-dose | 1.89 ± 0.252 | 1.44 ± 0.466 | — | 1.46 ± 0.589 | 1.43 ± 0.287 |
| Multiple-dose | — | — | — | 1.10 ± 0.181 | 1.87 ± 1.33 |
PK assessment of valganciclovir pre-dose and at hours 0.5, 1, 2, 4, and 6 post-dose on C1D1 and C2D1
| hours | Phase 1b Dose Escalation - 450 mg | Phase 1b Dose Escalation - 900 mg | Phase 2 RP2D - Capsule (VRx-3996) | Phase 2 RP2D - Tablet (VRx-3996) |
|---|---|---|---|---|
| Single-dose | 3.56 ± 1.06 | 3.13 ± 1.43 | 3.32 ± 1.10 | 2.17 ± 1.68 |
| Multiple-dose | — | — | 2.43 ± 0.697 | 2.61 ± 1.55 |
Collected over Up to approximately 2 years. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1b Dose Escalation Cohort 1 | 4/7 (57.1%) | 2/7 (28.6%) | 7/7 (100%) |
| Phase 1b Dose Escalation Cohort 2a | 4/5 (80%) | 2/5 (40%) | 5/5 (100%) |
| Phase 1b Dose Escalation Cohort 2b | 2/4 (50%) | 2/4 (50%) | 4/4 (100%) |
| Phase 1b Dose Escalation Cohort 2c | 4/4 (100%) | 1/4 (25%) | 4/4 (100%) |
| Phase 1b Dose Escalation Cohort 3 | 3/5 (60%) | 1/5 (20%) | 5/5 (100%) |
| Phase 2 Dose Expansion - Capsule | 17/30 (56.7%) | 11/30 (36.7%) | 22/30 (73.3%) |
| Phase 2 Dose Expansion - Tablet | 4/9 (44.4%) | 4/9 (44.4%) | 6/9 (66.7%) |
| Event | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Dose Expansion - Tablet |
|---|---|---|---|---|---|---|---|
| Tumour necrosisNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/7 | 0/5 | 0/4 | 1/4 | 0/5 | 0/30 | 0/9 |
| Acute kidney injuryRenal and urinary disorders | 0/7 | 0/5 | 1/4 | 0/4 | 0/5 | 1/30 | 0/9 |
| Enterocolitis viralInfections and infestations | 0/7 | 0/5 | 1/4 | 0/4 | 0/5 | 0/30 | 0/9 |
| PharyngitisInfections and infestations | 0/7 | 0/5 | 0/4 | 1/4 | 0/5 | 0/30 | 0/9 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/7 | 1/5 | 0/4 | 0/4 | 0/5 | 0/30 | 1/9 |
| PyrexiaGeneral disorders | 0/7 | 1/5 | 0/4 | 0/4 | 0/5 | 0/30 | 1/9 |
| Clostridium difficile colitisInfections and infestations | 0/7 | 1/5 | 0/4 | 0/4 | 0/5 | 0/30 | 0/9 |
| Left ventricular failureCardiac disorders | 0/7 | 1/5 | 0/4 | 0/4 | 0/5 | 0/30 | 0/9 |
| Drug hypersensitivityImmune system disorders | 0/7 | 1/5 | 0/4 | 0/4 | 0/5 | 0/30 | 0/9 |
| Systemic lupus erythematosusMusculoskeletal and connective tissue disorders | 0/7 | 0/5 | 0/4 | 0/4 | 1/5 | 0/30 | 0/9 |
| Event | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Dose Expansion - Tablet |
|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 1/7 | 4/5 | 0/4 | 2/4 | 2/5 | 8/30 | 2/9 |
| NauseaGastrointestinal disorders | 1/7 | 0/5 | 3/4 | 1/4 | 4/5 | 11/30 | 5/9 |
| VomitingGastrointestinal disorders | 1/7 | 0/5 | 3/4 | 0/4 | 2/5 | 6/30 | 3/9 |
| HeadacheNervous system disorders | 1/7 | 0/5 | 3/4 | 0/4 | 0/5 | 3/30 | 0/9 |
| FatigueGeneral disorders | 4/7 | 1/5 | 0/4 | 0/4 | 1/5 | 10/30 | 6/9 |
| Blood creatinine increasedInvestigations | 3/7 | 1/5 | 0/4 | 0/4 | 3/5 | 3/30 | 1/9 |
| Oedema peripheralGeneral disorders | 4/7 | 0/5 | 0/4 | 0/4 | 0/5 | 1/30 | 1/9 |
| ThrombocytopeniaGastrointestinal disorders | 2/7 | 2/5 | 0/4 | 2/4 | 0/5 | 5/30 | 0/9 |
| DiarrhoeaGastrointestinal disorders | 3/7 | 2/5 | 2/4 | 0/4 | 1/5 | 7/30 | 4/9 |
| PyrexiaGeneral disorders | 0/7 | 2/5 | 2/4 | 0/4 | 1/5 | 6/30 | 2/9 |
Starting valganciclovir dosage reductions based on creatinine clearance were allowed for participants with renal impairment.
| Age, Categorical(Participants) | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Dose Expansion - Tablet | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 2 | 4 | 3 | 4 | 14 | 3 | 34 |
| >=65 years | 3 | 3 | 0 | 1 | 1 | 16 | 6 | 30 |
| Age, Continuous(years) | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Dose Expansion - Tablet | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 55.0 ± 24.06 | 60.8 ± 20.44 | 45.3 ± 19.45 | 56.8 ± 10.56 | 44.0 ± 24.36 | 60.1 ± 16.97 | 63.4 ± 15.42 | 57.7 ± 18.42 |
| Sex: Female, Male(Participants) | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Dose Expansion - Tablet | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 1 | 2 | 2 | 1 | 2 | 12 | 4 | 24 |
| Male | 6 | 3 | 2 | 3 | 3 | 18 | 5 | 40 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Dose Expansion - Tablet | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 2 | 8 | 1 | 12 |
| Not Hispanic or Latino | 7 | 5 | 4 | 3 | 3 | 22 | 7 | 51 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Dose Expansion - Tablet | Total |
|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 0 | 0 | 2 | 1 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 1 | 0 | 1 | 2 | 0 | 5 |
| White | 6 | 4 | 2 | 3 | 3 | 24 | 8 | 50 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 2 |
| Region of Enrollment(Participants) | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Dose Expansion - Tablet | Total |
|---|---|---|---|---|---|---|---|---|
| United States | 7 | 5 | 4 | 3 | 3 | 20 | 9 | 51 |
| Brazil | 0 | 0 | 0 | 1 | 2 | 10 | 0 | 13 |
| Lymphoma or Lymphoproliferative Disorder Subtype(Participants) | Phase 1b Dose Escalation Cohort 1 | Phase 1b Dose Escalation Cohort 2a | Phase 1b Dose Escalation Cohort 2b | Phase 1b Dose Escalation Cohort 2c | Phase 1b Dose Escalation Cohort 3 | Phase 2 Dose Expansion - Capsule | Phase 2 Dose Expansion - Tablet | Total |
|---|---|---|---|---|---|---|---|---|
| Peripheral T-cell Lymphoma / Angioimmunoblastic T-cell Lymphoma | 1 | 2 | 1 | 0 | 0 | 7 | 2 | 13 |
| Diffuse Large B-cell Lymphoma | 1 | 1 | 0 | 0 | 0 | 5 | 3 | 10 |
| Extranodal NK/T-cell Lymphoma | 0 | 0 | 1 | 0 | 2 | 6 | 1 | 10 |
| Human Immunodeficiency Virus-Associated Lymphoma | 1 | 0 | 1 | 2 | 0 | 1 | 0 | 5 |
| Hodgkin Lymphoma | 2 | 0 | 0 | 1 | 1 | 7 | 1 | 12 |
| Immunodeficiency-Associated Lymphoproliferative Disorders | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 4 |
| Other B-cell Non-Hodgkin Lymphomas | 1 | 0 | 0 | 0 | 0 | 2 | 1 | 4 |
| Other T-cell Non-Hodgkin Lymphomas | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 2 |
| Post-Transplant Lymphoproliferative Disorders | 1 | 1 | 0 | 0 | 1 | 1 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2018 to primary completion in Apr 2023, 60 months.
Results were first posted in Mar 2025, 1 year 11 months after primary completion. A results delay was requested in Mar 2024.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nanatinostat · Valganciclovir
Lymphoproliferative Disorders →
Viracta Therapeutics, Inc.